NEWS
NORMAN, OKLA. – Following the establishment of a 12-member search committee representing key stakeholders across the University community, led by Randall Stephenson, The Athlete Group has been retained to assist the committee in the administration and search process for OU’s next Director of Athletics. TAG has served as a partner in other recent placements, including the General Manager of Football.
Inquiries and nominations for the OU Athletics Director position should proceed to the following web address: www.theathletegroup.com/OU-search.
About the University of Oklahoma
Founded in 1890, the University of Oklahoma is a public research university located in Norman, Oklahoma. As the state’s flagship university, OU serves the educational, cultural, economic and health care needs of the state, region and nation. For more information about the university, visit www.ou.edu.
About The Athlete Group
TAG is a boutique high-performance strategic consulting and advisory firm bringing extensive professional sports experience to the collegiate level. TAG partners with universities, athletic departments, and their coaches to provide guidance in executive search, player acquisition, contract negotiation, revenue generation and allocation, and help with modernizing organizational structure. For more information about TAG, visit www.theathletegroup.com.
University of Oklahoma College of Medicine Associate Professor Lee Jennings, M.D., chief of the Division of Geriatrics and Palliative Medicine in the Department of Internal Medicine, has been selected for the Hedwig van Ameringen Executive Leadership in Academic Medicine® (ELAM) program, one of the nation’s top leadership fellowships in academic health care.
The University of Oklahoma community came together once again in a powerful show of generosity during its annual Giving Day, raising over $29.6 million to support causes university-wide.
Results from a Phase 3 clinical trial offer new hope for patients with advanced pancreatic cancer, showing the experimental drug daraxonrasib significantly extended survival compared with chemotherapy alone. Researchers at the University of Oklahoma Health Stephenson Cancer Center enrolled patients in the global trial.
